TRANSLATING PLURIPOTENT STEM CELL DISCOVERIES TO THE CLINIC: PRECLINICAL, MANUFACTURING, AND REGULATORY STRATEGIES FOR SUCCESS
The International Society for Stem Cell Research (ISSCR) invites you to join us for the 2022 Symposium on Cell Manufacturing and Commercialization “Translating Pluripotent Stem Cell Discoveries to the Clinic: Preclinical, Manufacturing, and Regulatory Strategies for Success” which will take place at the, Boston Marriott Cambridge Boston, MA from November 17-19, 2022. Registration is open!
The meeting will bring together international academic and commercial scientists with expertise in the preclinical, clinical, and regulatory phases to discuss the critical processes and strategies in the successful development of PSC-derived therapies. Sessions will cover some of the latest thinking and approaches for selecting the cell line, characterizing the product and manufacturing considerations, managing the immune system, and working with regulators throughout the process. We hope you can join us in one of the world’s hubs of biotechnology.
ARMI | BioFabUSA will host a 1-hour workshop on November 19. The workshop will include lunch.
ARMI | BioFabUSA receives a limited number of discounted passes to the conference, if you are a member of ARMI and interested in attending ISSCR please reach out to the membership team at Outreach_Membership@armiusa.org.
The deadline to secure a discounted pass is November 2.
Rates:
The Advanced Regenerative Manufacturing Institute (ARMI) is a member-based, nonprofit organization whose mission is to advance the bioeconomy of the United States.
BioFabUSA, a program of ARMI, is a public-private partnership with more than 170 members, including companies, academic institutions and not-for profit organizations.
ARMI BioIndustries is the full-service development and manufacturing operation within the Advanced Regenerative Manufacturing Institute.
NextFab is the first foundry for American biotechnology. The mission of NextFab is to produce technological solutions that help the United States protect against and respond to health-security threats, enhance daily medical care and add to the U.S. bioeconomy.
BioFabUSA, a program of ARMI, is a public-private partnership with more than 170 members, including companies, academic institutions and not-for profit organizations.
